BIORON — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BIORON is a privately held, revenue-generating German biotech firm with over two decades of experience as a manufacturer and global distributor of molecular biology raw materials and diagnostic kits. The company has built a diversified portfolio across PCR enzymes, human DNA blocking agents, mRNA raw materials (NTPs, cap analogs), and ready-to-use pathogen detection kits, underpinned by ISO 13485 certification for medical device production. Its strategic acquisition of BIORON Diagnostics GmbH in 2023 strengthens its integrated diagnostics offering, positioning it to capitalize on growing demand in molecular diagnostics and mRNA therapeutics. With a team of over 10 employees, BIORON combines custom production services with a focus on high-concentration, lyophilization-friendly formats critical for diagnostic assay developers.

Infectious DiseaseOncology

Technology Platform

Expertise in manufacturing high-concentration, lyophilization-ready polymerases and enzymes; production of human DNA blocking agents (Cot I DNA) for hybridization assays; supply of mRNA raw materials (NTPs, cap analogs) and related analytical services.

Opportunities

The growing global molecular diagnostics market and the expansion of mRNA therapeutics create sustained demand for high-quality raw materials and specialized reagents.

BIORON's ISO 13485 certification and expertise in lyophilization-friendly formulations position it as a critical partner for diagnostic kit manufacturers seeking stable, compliant components.

The acquisition of its diagnostics arm allows it to capture more value along the supply chain by offering integrated solutions.

Risk Factors

BIORON faces intense competition from large, global life science reagent companies with greater resources and broader portfolios.

Its business is vulnerable to customer concentration risk and technological shifts that could reduce demand for PCR or mRNA-based products.

Maintaining stringent quality control under ISO 13485 is essential but costly, and any failure could severely damage its reputation as a supplier to the medical industry.

Competitive Landscape

BIORON competes in a crowded field dominated by multinational giants like Thermo Fisher Scientific, Merck KGaA, and Qiagen in the life science reagents space, and with specialized enzyme suppliers like New England Biolabs. Its differentiation lies in its focus on high-concentration, lyophilization-ready formats, certified medical-grade production, and a niche expertise in human DNA blocking agents. In mRNA raw materials, it competes with companies like TriLink BioTechnologies and NEB.

More companies in Diagnostics & Precision Medicine →More companies in Germany →